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Abstract Resveratrol is a natural compound that has been
intensely studied due to its role in cancer prevention and
potential as an anti-cancer therapy. Its effects include
induction of apoptosis and senescence-like growth inhibi-
tion. Here, we report that two cancer cell lines (U-2 OS and
A549) differ significantly in their molecular responses to
resveratrol. Specifically, in U-2 OS cells, the activation of
the p53 pathway is attenuated when compared to the acti-
vation in A549 cells. This attenuation is accompanied by a
point mutation (458: CGA?TGA) in the PPM1D gene and
overexpression of the encoded protein, which is a negative
regulator of p53. Experimentally induced knockdown of
PPM1D in U-2 OS cells resulted in slightly increased
activation of the p53 pathway, most clearly visible as
stronger phosphorylation of p53 Ser37. When treated with
nutlin-3a, a non-genotoxic activator of p53, U-2 OS and
A549 cells both responded with substantial activation of
the p53 pathway. Nutlin-3a improved the clonogenic sur-
vival of both cell lines treated with resveratrol. This
improvement was associated with lower activation of
DNA-damage signaling (phosphorylation of ATM, CHK2,
and histone H2AX) and higher accumulation of cells in the
G1 phase of the cell cycle. Thus, the hyperactivation of p53
by nutlin-3a helps to preserve the replicative potential of
cells exposed to resveratrol.
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Introduction
In vivo studies have revealed that resveratrol delays cancer
development and improves the health of mice on a high-
calorie diet [1, 2]. Resveratrol is also considered to be an
anti-aging molecule, although different groups have pub-
lished discordant results on this issue (reviewed in [3]).
In vitro experiments with cancer cell lines indicate that
resveratrol can induce cell-cycle inhibition, senescence-
like growth inhibition, or apoptosis [4]. The mechanistic
explanation of results from animal studies are unsatisfac-
tory, partially because of the different concentrations of
resveratrol present in the extracellular matrix of target cells
of experimental animals and in cancer cell lines treated
with resveratrol in vitro (reviewed in [5]).
At concentrations in the range 40–80 lM, resveratrol
activates DNA-damage signaling, e.g., phosphorylation of
histone H2AX on Ser139 [6–8], which can be phosphory-
lated by DNA damage-activated kinases [9]. A recently
published study showed that resveratrol can be genotoxic
even at concentrations as low as 5 lM, which can be
achieved in laboratory animals by oral administration [10].
The mechanism underlying the genotoxic activity of res-
veratrol is not well understood. Resveratrol can inhibit
DNA polymerases a and d as well as DNA topoisomerase
II [8, 11], so it has been hypothesized that resveratrol
induces DNA damage by inhibiting enzymes that partici-
pate in DNA replication and/or repair (reviewed in [12]).
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This hypothesis predicts that cells in the DNA synthesis
(S) phase would be the most sensitive to resveratrol.
Activation of DNA-damage signaling leads to activa-
tion of the p53 pathway, whose role is to stop the cell
cycle and either facilitate DNA repair or permanently
inhibit cell growth by inducing cellular senescence or
apoptosis. For example, double-strand DNA breaks trigger
activation of ATM kinase by autophosphorylation of
Ser1981; activated ATM then phosphorylates Thr68 of
CHK2 kinase. Activated CHK2 and ATM both phos-
phorylate p53 at the N-terminus, thereby stabilizing p53
by preventing its association with MDM2, the ubiquitin
ligase and negative regulator of p53 (reviewed in [13]).
Activated p53 induces transcription of the gene encoding
p21, which is the major effector of cell-cycle inhibition
(reviewed in [14]). p53 transcriptionally induces its neg-
ative regulators, the MDM2 and WIP1 proteins ([15] and
references therein). The latter protein can dephosphorylate
and inactivate p53 as well as ATM and CHK2 [16–18].
The p53 pathway can also be activated non-genotoxically
by nutlin-3a, an experimental drug designed to bind
MDM2 specifically in its p53-binding pocket. Nutlin-3a
prevents MDM2 from binding and destabilizing p53,
leading to accumulation of high levels of p53 and
upregulation of some p53-dependent genes, e.g., p21 and
MDM2 [19].
In a previous study, we showed that resveratrol activates
the p53 pathway in A549 and U-2 OS cells, as indicated by
the accumulation of p53 protein and by the phosphoryla-
tion of p53 on Ser15 and Ser37. However, p21 was effi-
ciently upregulated only in A549 cells, suggesting that the
resveratrol-induced activation of the p53 pathway was
attenuated in U-2 OS cells when compared with A549
cells. Despite their weak activation of the p53 pathway,
U-2 OS cells exposed to resveratrol exhibited senescence-
like growth inhibition. Moreover, we noticed strong dif-
ferences between resveratrol-treated A549 and U-2 OS
cells regarding expression pattern of the major cell-cycle
regulators, e.g., BRCA1, cyclin B1, and RB [7]. The goal
of this study was to explore further the molecular differ-
ences between A549 and U-2 OS cells, which could
account for the different modes of p53 pathway activation.
We conjectured that attenuation of p53 activation in U-2
OS cells might be specific to a subset of stress factors, such
as those that trigger extensive post-translational modifica-
tions of p53, e.g., DNA damage. Hence, we planned to
compare the status of nutlin-3a-induced p53 activation
between A549 and U-2 OS cells. Moreover, we wanted to
explore how nutlin-3a would modify the response of cells
to genotoxic doses of resveratrol. The results of these
experiments should help us understand the molecular
mechanisms underlying the cytostatic activity of resvera-
trol, which is still a matter of debate.
Materials and methods
Cell culture, treatment, cytometric analysis of DNA
content, and clonogenic assays
U-2 OS (human osteosarcoma, ATCC), A549 (human lung
adenocarcinoma, ATCC), and GM07492 (normal human
fibroblasts, Coriell Cell Repositories, Camden, NJ) cells
were grown at 37 C in an atmosphere containing 5 % CO2
in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-
Aldrich, St. Louis, MI) supplemented with 10 % (U-2 OS,
A549) or 15 % (GM07492) fetal bovine serum (Gibco-
Invitrogen, Carlsbad, CA) and penicillin–streptomycin
solution (Sigma-Aldrich). GM07492 cells were used
between passages 11 and 12.
The following stock solutions of chemicals were used:
resveratrol (100 mM in DMSO; Sigma-Aldrich), nutlin-3a
(10 mM in DMSO; Cayman Chemical, Ann Arbor, MI).
Stock solutions were dissolved in culture medium to obtain
the required concentration of the chemicals (50 lM res-
veratrol or 5 lM nutlin-3a). Control cells were treated with
medium containing indicated concentration of DMSO
(0.05 or 0.1 %).
Cell-cycle profiles were obtained by FACS analysis
(FACSCanto flow cytometer, Becton–Dickinson, Franklin
Lakes, NJ) following trypsinization of attached cells, eth-
anol fixation, RNase treatment, and propidium iodide (PI)
staining.
For clonogenic assays, cells were seeded into 6-well
plates. Starting the next day, the cells on experimental
plates were treated for 96 h with 50 lM resveratrol, 5 lM
nutlin-3a, or both substances; the control cells were mock-
treated. After treatment, the cells were extensively washed
and allowed to recover in fresh medium for 24 h. Subse-
quently, the cells were trypsinized and counted, and 1,000
cells from each sample were seeded into 6 cm plates
containing 5 ml of fresh medium. After incubation for 9
(A549) or 12 (U-2 OS) days, colonies were fixed with 1:1
methanol:acetone and visualized with crystal violet. For
each data point, large colonies were counted on two plates
from at least three independent experiments.
Suppression of WIP1 expression by lentivirus-delivered
shRNA
The expression of WIP1 protein in U-2 OS cells was
suppressed using transduction-ready lentiviral particles
purchased from Santa Cruz Biotechnology (Santa Cruz,
CA). The manufacturer’s protocol was followed. Control
cells were transduced with lentiviral particles (from the
same manufacturer) encoding scrambled shRNA particles
that do not induce specific degradation of any known
mRNA. Positively transduced cells were selected with
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puromycin. Due to high transduction efficiency, clonal
selection was not required. The efficiency of knockdown
was monitored by Western blotting. The day before treat-
ment, the cells were trypsinized, seeded into new plates,
and incubated in puromycin-free medium. Other resvera-
trol treatment conditions were as described above.
Immunofluorescence staining of histone H2AX
phosphorylated on serine 139 (cH2AX)
Staining was performed as described previously [7, 20].
Cells on Lab-Tek II slides (NUNC, Roskilde, Denmark)
were fixed for 2 min at room temperature with 3.7 % for-
malin in PBS (Sigma-Aldrich), washed, and then perme-
abilized in PBS containing 0.5 % Triton X-100 (Sigma-
Aldrich) for 10 min. After washing, the cells were incu-
bated in blocking solution (5 % BSA and 0.15 % glycine in
PBS) at room temperature for 30 min. After 2 h incubation
with anti-phospho-Ser139 histone H2AX antibody
(JBW301, Upstate-Millipore, Billerica, MA; diluted 1:500
in blocking solution), the cells were extensively washed
and incubated with Texas Red-conjugated anti-mouse IgG
antibody (Vector Laboratories, Burlingame, CA), diluted
1:300. The stained cells were embedded in Vectashield
with DAPI (Vector Laboratories) and were observed using
a Nikon Eclipse E80i fluorescence microscope.
Western blotting
Control and treated cells growing on culture plates were
harvested by trypsinization. For preparation of whole-cell
lysates, PBS-washed cell pellets were frozen on dry ice and
stored at -70 C. Subsequently, the frozen cell pellets
were suspended in IP buffer (50 mM Tris–HCl, pH 8.0;
120 mM NaCl; 0.5 % NP-40) supplemented with protease
inhibitors (PMSF, pepstatin A, aprotinin, and leupeptin)
and Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich).
After incubation on ice for 20 min, lysates were cleared by
centrifugation (14,000 rpm, 4 C, 20 min). Subsequently,
two volumes of cleared lysate was mixed with one volume
of solution containing 150 mM Tris (pH 6.8), 6 % SDS,
30 % glycerol, 0.01 % bromophenol blue, and 7.5 % b-
mercaptoethanol. Lysates were then denatured (95 C,
5 min), chilled on ice, and stored at -70 C.
Nuclear extracts were prepared by a method described
previously [7]. After trypsinization and washing with PBS,
cell pellets were treated with ice-cold EC buffer (20 mM
Tris, pH 7.6; 10 mM KCl; 2 mM MgCl2; 1 mM DTT;
0.5 mM EGTA; 0.5 % NP40; 2.5 % glycerol) supple-
mented with the protease and phosphatase inhibitors
mentioned above. The suspension was incubated on ice for
10 min. Subsequently, the samples were centrifuged at
3109g at 4 C for 10 min. The cytoplasmic fractions in the
supernatants were discarded, and the pellets enriched in
cell nuclei were frozen at -70 C. After thawing on ice,
pellets were lysed on ice for 20 min with RIPA buffer
(0.5 % NP40, 0.5 % sodium deoxycholate, 0.1 % SDS in
PBS) supplemented with protease and phosphatase inhibi-
tors. After centrifugation and denaturation as described
above, the nuclear extracts were stored at -70 C.
Subsequently, 10–50 lg aliquots of whole-cell lysates
or nuclear extracts were separated by 6 or 11 % SDS-
PAGE and electrotransferred onto PVDF membranes. The
membranes were blocked for 1 h at room temperature in
blocking solution (5 % skim milk solution in PBS with
0.1 % Tween-20) and incubated with the indicated primary
antibody. The following antibodies were from Cell Sig-
naling Technology: anti-phospho-Ser1981 ATM (D6H9),
anti-ATM (D2E2), anti-acetyl-Lys382 p53, anti-phospho-
Ser15 p53 (rabbit polyclonal antibody), anti-phospho-
Ser20 p53, anti-phospho-Ser37 p53, anti-phospho-Ser392
p53, anti-CHK2 (rabbit polyclonal antibody), anti-phos-
pho-Thr68 CHK2, anti-phospho-Ser807/811 RB, and anti-
PLK1 (208G4). Anti-BRCA1 (D-9), anti-CDC2 (17), anti-
p53 (DO-1), and anti-p21WAF1 (F-5), anti-MDM2 (HDM2-
323) antibodies were from Santa Cruz Biotechnology.
Anti-retinoblastoma protein (RB) antibody (clone
mAB245) was from Chemicon International, and anti-14-
3-3r (Ab14116) and anti-PPM1D (WIP1) antibodies
(Ab31270) were from Abcam (Cambridge, UK). HSC70
loading control was detected using the B-6 antibody (Santa
Cruz Biotechnology). All incubations with primary anti-
bodies were performed overnight at 4 C in blocking
solution. The secondary antibodies were HRP-conjugated
and detected by chemiluminescence.
Semi-quantitative real-time PCR
Total RNA samples were prepared using the RNeasy mini
kit according to the manufacturer’s protocol (Qiagen,
Hilden, Germany). cDNAs were synthesized using MuLV
reverse transcriptase and random hexamers (Applied Bio-
systems, Foster City, CA). Measurements of p21, MDM2,
PPM1D, and b-actin (internal reference) mRNA levels
were performed using Real-Time 29 PCR Master Mix
SYBR (A&A Biotechnology, Gdynia, Poland) with oligo-
nucleotide sequences GTG GAC CTG TCA CTG TCT TG
and GAT TAG GGC TTC CTC TTG G for p21, GAG ACC
CTG GTT AGA CCA AAG C and GCA CGC CAA ACA
AAT CTC C for MDM2, CTC AAT GTG CCA GGA CCA
AGA G and TAT CTG CTC GGA GCA TAC GCT G for
WIP1 (PPM1D), and GCA AGC AGG AGT ATG ACG
AG and CAA ATA AAG CCA TGC CAA TC for b-actin
mRNA [21]. PCR was performed using a CFX96 Real-
Time System (Bio-Rad, Hercules, CA). In each PCR run,
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the cDNA samples were amplified in triplicate. The rela-
tive quantification of the mRNAs for p21, WIP1, and
MDM2 was performed using the DDCT method, with b-
actin as the reference. Means and standard deviations were
calculated from two independent treatments.
RT-PCR and sequencing of the WIP1 gene (PPM1D)
coding sequence
RNA and cDNA samples from untreated A549 and U-2 OS
cells were prepared as described in the previous section.
RT-PCR amplifications in the presence of 6.5 % DMSO
were performed using AmpliTaq Gold polymerase
(Applied Biosystems); hence, the reactions were started
with a 10 min incubation at 95 C to activate the enzyme.
Subsequently, 40 cycles of amplification (94 C, 30 s;
58 C, 15 s; 72 C, 75 s) were performed. The PPM1D
cDNA sequence was amplified as two overlapping frag-
ments encompassing the coding region. The primer
sequences are given in the 50?30 direction. The 50 frag-
ment (1,012 bp) was amplified with the following primers:
WIP-P1, GGC GTC GTC GAA GAT AAA CA; WIP-RT1,
GTC AAG AGT GTG GAC ACT TG. The 30 fragment
(1,116 bp) was amplified with the following primers: WIP-
RT2, TTG TGG TGT CACCTG AAC CAG; WIP-P12,
CAA GCA AGT ACA AGG CCA GGA. Subsequently, the
PCR products were prepared for sequencing by exonucle-
ase I and shrimp alkaline phosphatase digestion of unin-
corporated primers and deoxynucleotides. Prepared PCR
products were sequenced using DigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems), and the
sequences were acquired using a Genetic Analyzer 3500
(Applied Biosystems). The 50 fragment was sequenced
using the following primers: WIP-SQ1, AAC AAT AGT
TGG CCG GCG AG; WIP-RT3, AGA AGG GTT TCA
CCT CGT CC. The 30 fragment was sequenced using the
following primers: WIP-RT4, GAG GGT ATG ACT ACA
CCT TG; WIP-SQ12, GTT CAA CAT CGG CAC CAA
AT. Genomic DNA from A549 and U-2 OS cells was
isolated by the chloroform extraction and ethanol precipi-
tation method using the Genomic DNA Purification kit
(Fermentas, Vilnius, Lithuania). Exon 6 of PPM1D was
amplified with the following primers: WIP-P11, CAA GCA
AGT ACA AGG CCA GGA; WIP-P12 (see above). Exon 6
was amplified from genomic DNA as a template using
AmpliTaq Gold polymerase in the presence of 5.2 %
DMSO. Thirty-five cycles of amplification (94 C, 30 s;
60 C, 30 s; 72 C, 45 s) were performed. The fragment
was sequenced as described above with the following
primers: WIP-SQ11, TCA CAT GCA TAG ATT TGT
TGA GTT C; WIP-SQ12 (see above).
Results
U-2 OS cells exposed to resveratrol exhibit attenuated
upregulation of mRNA and proteins encoded by p53
target genes
Despite accumulation of p53 protein induced by resvera-
trol, U-2 OS cells exhibited attenuated upregulation of p53
target genes (e.g., those encoding p21 and MDM2) when
compared with A549 cells. This attenuation was visible at
both the protein (Fig. 1a) and mRNA levels (Fig 1b).
Potentially, insufficient post-translational modification of
p53 could be the source of the apparently weaker p53
activity in U-2 OS cells. Previously, we found that in both
cell lines, p53 was phosphorylated at Ser15 and Ser37,
although the level of p53 with phosphorylated Ser37 was
slightly higher in A549 cells [7]. This observation was
confirmed in this study both in nuclear extracts (not shown)
and in whole-cell lysates prepared in a separate experiment
(Fig. 2). Moreover, in this study we observed that the other
crucial modifications of p53 (phosphorylation of Ser20 and
Ser392 as well as acetylation of Lys382) were similar in both
cell lines (Fig. 2). Thus, the source of relatively weak p53
pathway activation in resveratrol-treated U-2 OS cells has
not been determined, although it is associated with the
lower phosphorylation level of Ser37. We hypothesize that
the reduced ability of p53 to activate its target genes in U-2
OS cells could result from deficiencies in post-translational
modifications of residues that were not studied by us, and/
or from altered activities of proteins functionally associated
with p53.
The resveratrol-induced cell-cycle inhibition of A549
cells is associated with strong downregulation
of proteins involved in regulation of the G2/M
checkpoint
The mechanistic basis of cell-cycle inhibition in U-2 OS
cells exposed to resveratrol is not known [7]. The low
activity of p21 in resveratrol-treated U-2 OS cells mani-
fests as the persistent phosphorylation of RB protein
(Fig. 3). Accumulated p21 inhibits RB phosphorylation
(reviewed in [22]). Previously, we found that the different
degrees of p53 pathway activation between A549 and
U2OS cells were associated with differences in the
expression levels of crucial cell-cycle regulators [7]. Strong
upregulation of p21 in A549 was associated with repression
of BRCA1, cyclin B1, and the phosphorylated form of RB.
In this study, we expanded this analysis to other regulators
of the G2/M checkpoint (Fig. 3). Using an antibody that
specifically recognizes the phosphorylation of RB at Ser807
5016 Mol Biol Rep (2013) 40:5013–5026
123
and Ser811, we confirmed the inhibition of RB phosphory-
lation in A549 cells. Moreover, in these cells we detected
strong repression of cyclin-dependent kinase CDC2
(CDK1), which, in complex with cyclin B1, is the major
kinase that induces the G2/M transition. Interestingly, A549
cells also exhibited strong repression of another kinase,
PLK1, which is crucial for entering mitosis (reviewed in
[23]). Thus, unlike U-2 OS cells, resveratrol-treated A549
cells exhibited coordinated repression of major regulators of
cell-cycle progression (cyclin B1, CDC2, BRCA1, phos-
phorylated RB, and PLK1). The cell-cycle inhibition of
A549 cells treated with resveratrol can be explained in
molecular terms: they cannot progress to mitosis due to a
shortage of activated kinases (CDC2/cyclin B1, PLK1) that
are crucial for starting cell division (reviewed in [23]). The
mechanism underlying cell-cycle inhibition of U-2 OS cells
exposed to resveratrol is unknown; furthermore, these cells
also do not upregulate 14-3-3r, the product of another p53
target gene involved in G2 arrest [24] (Fig. 3b).
Cell-cycle inhibition of resveratrol-treated U-2 OS cells
is associated with persistent signaling through the ATM
pathway
It is plausible that U-2 OS cells have an unidentified defect in
p53 activation that leads to relatively weak upregulation of
target genes during resveratrol exposure. Hypothetically, such
a defect might involve a mechanism upstream of the p53
signaling pathway. In response to DNA damage, p53 is
phosphorylated by the ATM and CHK2 kinases (reviewed in
[25]). CHK2 is activated by ATM-mediated phosphorylation
[26]. To examine the activation status of these p53 regulators,
we monitored the phosphorylation of ATM Ser1981 and CHK2
Thr68. The ATM pathway was activated in both cell lines. In
A549 cells, CHK2 phosphorylation peaked at the 30 h time
point and diminished after 72 and 96 h (Fig. 3b). By contrast,
in U-2 OS cells, CHK2 phosphorylation peaked after 96 h.
Thus, the signaling through the ATM-CHK2 pathway differed
between the two cell lines: A549 cells exhibited activation and
subsequent repression of the signaling, whereas in U-2 OS
cells the signaling persisted for 96 h. Similar patterns of
H2AX phosphorylation have been reported previously [7].
U-2 OS cells overexpress PPM1D gene, which encodes
a negative regulator of the p53 pathway, WIP1
We hypothesized that repression of CHK2 phosphorylation
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Fig. 1 a Expression of p53 and proteins encoded by p53-regulated
genes (p21 and MDM2). Whole-cell lysates of untreated cells (U) and
of cells treated for the indicated number of hours with 50 lM
resveratrol were analyzed. HSC70 is a loading control. b Changes in
the levels of mRNAs encoding MDM2 or p21, measured by semi-
quantitative real-time PCR in RNA samples isolated from untreated
(U) cells and from cells treated with resveratrol for 24 or 96 h. The
results represent the means and standard deviations from two
independent experiments









Fig. 2 Expression of p53 and its post-translationally modified forms
in whole-cell lysates from untreated cells (U) or from cells treated
with resveratrol for the indicated number of hours in a time-course
experiment. Phosphorylation of serines 15, 20, 37, and 392 and
acetylation of lysine 382 were examined
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was the result of strong activation of the p53 pathway. This
conjecture is based on data reported by others, who found
that WIP1 protein, the product of a p53-activated gene
(PPM1D), is able to dephosphorylate CHK2 [18]. Hence,
we analyzed the dynamics of WIP1 expression in whole-
cell lysates of U-2 OS and A549 cells treated with resve-
ratrol. As predicted, in A549 cells, WIP1 was upregulated
at the 72 and 96 h time points. Surprisingly, however, in
U-2 OS cells, WIP1 protein was overexpressed, and its
expression did not exhibit major changes in response to
resveratrol treatment (Fig. 3b).
Analysis of WIP1 expression in whole-cell lysates from
untreated A549 and U-2 OS cells, as well as those from
normal human fibroblasts (GM07492), revealed the lowest
expression in fibroblasts, intermediate expression in A549,
and the highest expression in U-2 OS cells (Fig. 4a).
Consistent with this, the expression of PPM1D mRNA
measured by semi-quantitative RT-PCR was about eight
times higher in U-2 OS cells than in fibroblasts (Fig. 4b).
Moreover, PPM1D mRNA expression increased in both
U-2 OS and A549 cell lines treated with resveratrol, but the
magnitude of the increase was greater in A549 cells
(Fig. 4c), further supporting the hypothesis that activation
of p53 pathway is attenuated in U-2 OS. High expression of
the PPM1D gene in U-2 OS cells is consistent with its role
in carcinogenesis. PPM1D is considered to be a proto-
oncogene due to its role in negative regulation of p53 and
its overexpression in breast, gastric, and pancreatic cancers,
as well as in other tumors (reviewed [15]). To exclude the
possibility that U-2 OS cells express a mutant form of the
gene, we sequenced the PPM1D cDNA amplified by RT-
PCR. Unexpectedly, we found a nucleotide substitution
(Fig. 5). This C?T transition at position 1604 of the ref-
erence sequence NM_003620 generates a nonsense muta-
tion in codon 458 (458:CGA?TGA, Arg ? STOP). The
location of C?T substitution at a CpG dinucleotide is
consistent with deamination of 5-methylcytosine as the
mutagenic mechanism [27]. This mutation was also visible
in heterozygous configuration in the genomic DNA of U-2
OS cells (Fig. 5) indicating that the wild-type and mutant
alleles of PPM1D are present in equal copy numbers. We
have not detected any other mutations in the coding regions
of cDNAs from U-2 OS cells. Because these cells con-
tained a major alteration in the gene encoding WIP1 pro-
tein, we hypothesized that the attenuated activation of the
p53 pathway in U-2 OS cells is caused by overexpression
of WIP1.
Knockdown of WIP1 protein in U-2 OS cells helps
to activate p53
To determine whether the increased expression of WIP1 in
U-2 OS cells is the cause of the relatively weak activation
of the p53 pathway, we performed a time-course experi-
ment on cells in which WIP1 had been knocked down. The
knockdown was performed using lentiviral particles con-
taining three specific constructs encoding 19–25 nt shR-
NAs targeting the PPM1D mRNA. Control cells were
transduced with control lentivirus. The successful knock-
down of WIP1 in U-2 OS did not result in the same
molecular response to resveratrol observed in A549 cells,
i.e., neither downregulation of RB phosphorylation nor
repression of CDC2 was observed (Fig. 6). However, at
early time points of resveratrol treatment or in untreated
cells, WIP1 knockdown resulted in slightly increased
expression of p21 and phosphorylated CHK2 (on Thr68).
This effect was reproducibly observed in independent
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Fig. 3 a Expression of crucial cell-cycle regulators in nuclear
extracts of untreated cells (U) or cells treated with resveratrol for
the indicated number of hours. RB-807/811 shows the phosphoryla-
tion of Ser807 and Ser811 of RB. The upper and lower arrows show,
respectively, the hyper- and hypophosphorylated forms of RB.
b Expression and phosphorylation status of kinases activated by
DNA damage (ATM and CHK2), expression of the phosphatase
acting on them (WIP1), and expression of PLK1 kinase in whole-cell
lysates of cells treated as in a. 14-3-3r is an important regulator of
G2/M progression
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stronger resveratrol-induced phosphorylation of p53 on
Ser37. To the best of our knowledge, this is the first study
showing that WIP1 expression modulates the phosphory-
lation of p53 on this residue. We also observed an influence
of WIP1 repression on p53 Ser15 phosphorylation. Thus,
downregulation of WIP1 in U-2 OS cells helps to activate
p53, but does not result in major changes in expression of
the cell-cycle regulators we examined (RB, CDC2).
Nutlin-3a upregulates the p53 pathway in both U-2 OS
and A549 cell lines and induces the accumulation of G1
phase cells in resveratrol-treated populations
To examine the mechanism of p53 activation in U-2 OS
cells more closely, we decided to determine whether the
p53 pathway could be activated by a non-genotoxic agent,
nutlin-3a, which apparently activates p53 in a way that
does not require extensive phosphorylation of p53 on key
serine residues [28]. In both cell lines, treatment with
nutlin-3a resulted in upregulation of p53 and accumulation
of the major p53 targets, p21 and MDM2 (Fig. 7a). As
expected, p53 activation induced by nutlin-3a was not
associated with strong phosphorylation of p53 at Ser15 and
Ser37. For unknown reasons, U-2 OS exhibited increased
acetylation of Lys382. Thus, in contrast to resveratrol,
nutlin-3a has the ability to activate the p53 pathway in U-2
OS strongly. Because nutlin-3a and resveratrol activated
the p53 pathway by different mechanisms, we next asked
how nutlin-3a modulates the resveratrol-induced activation
of p53 and DNA-damage signaling pathways. To the best
of our knowledge, this has not been previously addressed in
regard to resveratrol treatment, although earlier studies
have described how nutlin-3a modulates the biological and
molecular consequences of treating cells with various other
genotoxic agents (see Discussion). In A549 cells, nutlin-3a
attenuated p53 modifications induced by resveratrol
(Fig. 7a). This effect was not visible in U-2 OS cells (two
independent experiments showed this phenomenon). Based
on these results, we hypothesized that in A549 cells, nutlin-
3a attenuates signaling through the ATM pathway, result-
ing in lower levels of p53 modifications at Ser15 and Ser37.
To test this hypothesis, we looked for signs of ATM
pathway activation (phosphorylation of ATM at Ser1981
and of CHK2 at Thr68) in cells treated as in Fig. 7a. The
results were consistent with our hypothesis (Fig. 7b).
Nutlin-3a diminished the ATM phosphorylation in A549
cells treated with resveratrol. In U-2 OS cells, the major
sign of nutlin-induced ATM pathway downregulation was
lower phosphorylation of CHK2. To support further the
notion that the resveratrol-induced DNA-damage signaling
in U-2 OS cells is reduced by nutlin-3a, we determined the
percentage of cells containing high levels of cH2AX. After
96 h, the frequency of cH2AX-overexpressing cells was
significantly reduced in U-2 OS cells co-treated with both
substances, relative to cells exposed only to resveratrol
(Fig 7c, d). Moreover, we observed higher MDM2
expression in cells co-treated with resveratrol and nutlin-3a
than in cells treated only with resveratrol (Fig. 7a). These
findings are consistent with observations that high activity
of DNA damage-activated kinases destabilizes MDM2
[29]. Based on these results, we conclude that nutlin-3a has
the ability to reduce the activation of DNA-damage
WIP1

































Fig. 4 a The expression of WIP1 protein in whole-cell lysates
isolated from untreated normal human fibroblasts (NHF; GM07492)
and A549 or U-2 OS cancer cell lines. The position of molecular-
weight markers is shown on the left. b Expression of mRNA encoding
WIP1, measured by semi-quantitative real-time PCR in RNA samples
from the cells shown in (a). The results represent the means and
standard deviations from two independently isolated RNA samples.
c Changes in the levels of mRNA encoding WIP1, measured by semi-
quantitative real-time PCR in RNA samples isolated from untreated
cells (U) or from cells treated for 24 or 96 h with resveratrol. The
level in the untreated population of either cell line was defined as 1.
The results represent the means and standard deviations from two
independent experiments
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signaling. To explain this, we hypothesized that nutlin
somehow prevents the formation of DNA damage in cells
exposed to resveratrol. Some observations indicate that
resveratrol induces DNA damage mostly in cells that are
replicating their DNA (reviewed in [12]). If nutlin-3a
prevents the cells from entering the S phase of the cell
cycle, it might diminish the induction of DNA damage by
resveratrol. The results of a cytometric analysis were
consistent with this hypothesis (Fig. 8). As we previously
reported [7], resveratrol-treated cells accumulated in S or
late S/G2 phase of the cell cycle. Nutlin-3a alone blocked
both cell lines either in G1 or in G2 (Fig. 8), consistent
with data published by others [30]. S phase cells were
virtually absent in populations treated with nutlin-3a for
96 h. In co-treated cell populations, the frequency of cells
in G1 phase significantly increased in both cell lines. Thus,
diminished ATM pathway activation resulting from nutlin-
3a co-treatment is associated with inhibition of the cell
cycle before the DNA replication phase.
Nutlin-3a treatment also helped us to identify the likely
source of differences in the expression patterns of PLK1
and CDC2 between U-2 OS and A549 cells exposed to
resveratrol for extended periods of time (Fig. 3). Based on
data published by others showing that the genes encoding
CDC2 and PLK1 are repressed by p53 [31, 32], we con-
jectured that repression of CDC2 and PLK1 in A549 cells,
Fig. 5 Electropherogram showing a mutation in the gene encoding
WIP1 (PPM1D) detected in the cDNA of U-2 OS cells (right, upper
panel). The upper-left panel shows the relevant fragment of an
electropherogram from wild-type cDNA sequence detected in A549
cells. The position of the mutant nucleotide is indicated by arrows.
Note that in the electropherogram of U-2 OS cells, both wild-type and
mutant sequences are visible, indicating that both forms of mRNA are
expressed. The mutation 1604:C?T (coordinates according to
GenBank sequence, under Accession NM_003620) generates a stop
codon in place of amino-acid residue 458. The lower panels present
the relevant electropherograms of the genomic sequence, zoomed in
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Fig. 6 Expression of DNA-damage signaling proteins (ATM,
CHK2), their phosphorylated forms, p53, and post-translationally
modified p53, as well as the major cell-cycle regulators (p21, CDC2,
RB phosphorylated on Ser807/811), examined in whole-cell lysates
from untreated U-2 OS cells (U) or from cells treated with resveratrol
for the indicated number of hours in a time-course experiment. The
pairs represent control cells (-) and WIP1-knockdown cells (?);
knockdowns were performed using lentivirus-delivered shRNA
molecules. The efficiency of knockdown is shown by immunodetec-
tion of WIP1 protein
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and their lack of repression in U-2 OS cells, were conse-
quences of differences in the activation status of the p53
pathway. Indeed, this apparently was the case. Nutlin-3a
alone strongly repressed PLK1 and CDC2 in A549 cells
(Fig. 7a). Moreover, nutlin-3a was able to repress the two
proteins in U-2 OS cells, even though these cells did not
repress these proteins in response to resveratrol treatment.
We conclude that when U-2 OS cells are treated with
resveratrol, p53 can neither strongly upregulate p21 and
MDM2 nor strongly repress PLK1 and CDC2; however,
when p53 is activated by nutlin-3a, it efficiently activates
and represses the p53-regulated genes.
Nutlin-3a helps to preserve the replication potential
of resveratrol-treated cells
Next, we asked whether nutlin-3a could modify the fate of
resveratrol-treated cells. Both nutlin-3a and resveratrol,
acting alone or in combination, were able to inhibit the
growth of both cell populations after 96-h treatments
(Fig. 9a). Previously, we showed that resveratrol
significantly decreased the clonogenic potential of both cell
lines. This finding, together with the morphological and
biochemical characteristics of the treated cells, indicated
the induction of senescence-like growth inhibition [7]. In
this study, we found that even though nutlin strongly
inhibited growth of the cell population (Fig. 9a), it did not
induce a very strong change in the clonogenic potential of
cells (Fig. 9b, c). Consistent with previous results, we
found that resveratrol significantly reduced the clonoge-
nicity of both cell lines, although we noticed that U-2 OS
cells were slightly more sensitive in this assay. Unex-
pectedly, however, nutlin-3a helped to preserve the repli-
cation potential of resveratrol-treated cells of both lines
(Fig. 9b, c). Thus, even though both resveratrol and nutlin-
3a could activate p53, only resveratrol strongly reduced
clonogenic potential. Moreover, nutlin-3a had a dominant
effect over resveratrol with respect to influence on clono-
genic growth potential. Thus, increased activation of the
p53 pathway induced by nutlin-3a did not reduce growth,
but instead helped to preserve growth potential, in cells that
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Fig. 7 a Expression of the
indicated proteins in whole-cell
lysates of cells treated for 96 h
with 50 lM resveratrol (R),
5 lM nutlin-3a (N), or co-
treated with both substances
(RN). b The expression of
DNA-damage signaling proteins
(ATM and CHK2) and their
phosphorylated forms (ATM-
Ser1981, CHK2-Thr68) in
whole-cell lysates of cells
treated as in
a. c Immunocytochemical
staining of histone H2AX
phosphorylated on Ser139
(cH2AX) in U-2 OS cells
treated for 96 h with resveratrol
or with resveratrol and nutlin
(upper photographs). The
locations of cell nuclei were
visualized by DAPI staining.
d The frequency of U-2 OS cells
with upregulated cH2AX; cells
were treated as in a. Staining
was performed after 96 h
treatment. Means and standard
deviations are shown. At least
400 cells in two independent
experiments were examined
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Discussion
The results of this study demonstrate that the p53 pathway,
activated by the non-genotoxic agent nutlin-3a, can coun-
teract the loss of replicative potential induced by a geno-
toxic dose of resveratrol. The protective mechanism of
nutlin-3a may be complicated, but our observations are
consistent with the hypothesis that nutlin-3a arrests the cell
cycle at a phase when the cells are less sensitive to the
genotoxic activity of resveratrol. Nutlin-3a markedly
increases the frequency of resveratrol-treated cells arrested
with G1-phase DNA content (Fig. 8). Moreover, nutlin-3a
reduces the activation level of the DNA-damage signaling
pathway (ATM, CHK2, and histone H2AX). We speculate
that resveratrol induces replication stress, e.g., by inhibit-
ing the activity of DNA polymerases [11]. This in turn
elevates DNA-damage signaling, p53 activity, and stress-
induced senescence, leading to low clonogenic potential.
When treated with nutlin-3a, cells preferentially arrest
before or after the DNA replication phase, thereby
decreasing the chance of DNA damage formation by res-
veratrol. Consequently, activation of DNA-damage sig-
naling is low, and cells have normal replicative potential
when nutlin-3a and resveratrol are removed from the cul-
ture medium.
Our hypothesis is consistent with the observations of
Kranz and Dobbelstein [30], who revealed that nutlin-3a
protects cells against the S phase-specific chemotherapeu-
tic agent gemcitabine. The same authors found that nutlin-
3a pretreatment increased long-term survival and decreased
apoptosis in U-2 OS cells irradiated with UV. A similar
protective effect of nutlin-3a was observed in keratinocytes
[33]. Moreover, Carvajal et al. [34] found that nutlin-3a
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Fig. 8 The cell-cycle distribution of untreated cells (U) or cells
exposed to resveratrol (Res), nutlin-3a (Nut), or the combination of
both substances (Res?Nut) for 96 h. The horizontal axis shows DNA
content. The values for G1- and G2/M-phases are marked. The
vertical axis shows the cell count
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cancer cells with wild-type p53 against the cytotoxicity of
paclitaxel. The results of our study and the aforementioned
papers may be relevant to understanding the mechanisms
underlying the radio- and chemo-resistance of some cancer
cells. If p53 is activated by a non-genotoxic mechanism, it
may help cancer cells to survive treatment with S phase- or
M phase-specific agents and restart cell divisions when the
exposure ends. Thus, p53-negative tumors may be more
sensitive to some drug combinations, as long as cancer
cells are able to undergo p53-independent death.
Our findings and the results of others [30, 33, 34]
apparently contrast with data showing that nutlin-3a sen-
sitizes cancer cells to radiation [35, 36] or potentiates the
cytotoxic activity of anti-cancer drugs in solid tumors [37].
These discrepancies may result in part from the different
kinetics of nutlin-3a treatment, and/or measurements of
different endpoints, in each study. For example, Cao et al.
[35] showed by clonogenic assay that nutlin-3a sensitized a
lung-cancer cell line to radiation. However, the nutlin-3a
treatment was started just before irradiation and was con-
tinued 48 h afterward, so it is possible that nutlin-3a did
not have time to prevent cells from entering the most
sensitive phase of the cell cycle. A similar radiosensitizing
effect of nutlin-3a in a clonogenic assay of laryngeal car-
cinoma cells was detected by Arya et al. [36]; again,
however, the nutlin-3a treatment was performed short time
(30 min) before irradiation.
The protective role of nutlin-activated p53 shows some
similarity to the results of in vivo experiments, in which
p53 activity in mice was elevated either by the expression
of an extra copy of the p53 gene [38] or through genetic
downregulation of the MDM2 protein [39]. These geneti-
cally engineered mice exhibited decreased cancer inci-
dence without signs of accelerated aging. Thus, p53
moderately overexpressed in a non-genotoxic way can
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Fig. 9 a Growth-inhibitory
effect of resveratrol and nutlin-
3a in U-2 OS and A549 cells in
a short-term assay. Equal
numbers of cells were seeded
onto culture dishes at the start of
the experiment. The next day,
control cells were mock-treated
while experimental cells were
treated with resveratrol, nutlin,
or a combination of both
substances. After 96 h, the
attached cells were washed,
trypsinized, and counted. The
graph was drawn from means
and standard deviations from
two independent experiments
performed in triplicate. The
number of cells on control
dishes after 96 h culture is
considered as 100 %. Note that
a logarithmic scale is used.
b The effects of resveratrol,
nutlin, and the combination of
both substances on the
clonogenic potential of U-2 OS
and A549 cells. The vertical
axis shows the relative number
of clones, which was defined as
1 for the untreated cells. The
graphs show the means and
standard deviations from three
(U-2 OS) or four (A549)
independent experiments. The
t test for two samples was used
to determine statistical
significance. c Example of
plates from the clonogenic
experiment. Colonies on 6 cm
plates were stained with crystal
violet
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p53 under some experimental conditions has also been
observed by others [40]. A protective role of p53 has also
been suggested by the aforementioned authors, who found
that nutlin-3a pretreatment protected against UV-induced
toxicity [33]. Thus, accumulating evidence suggests that
p53, at least under specific circumstances, acts as a survival
factor.
We observed WIP1 overexpression in U-2 OS cells.
This was not surprising, because WIP1 gene amplification/
overexpression has been detected in adenocarcinomas of
the breast, ovary, and pancreas, in gastric carcinomas, and
in other cancers, where it was usually associated with poor
prognosis (review in [15]). WIP1 knockout mice are viable
and cancer-resistant, but they display a range of abnor-
malities in male individuals including runting, reproductive
organ atrophy, reduced fertility, and reduced longevity.
Knockout mice of both sexes suffer from immunological
abnormalities (reviewed in [15]).
In our study, knockdown of WIP1 increased phosphor-
ylation of CHK2 on Thr68, consistent with the finding of
Fujimoto et al. [41], who showed that WIP1 is able to
dephosphorylate this residue. Moreover, we found that the
knockdown resulted in higher phosphorylation of p53 on
Ser37 and higher expression of p21. Elevated levels of p21
in cells from WIP1 knockout mice have also been observed
by others [42]. Thus, overexpressed WIP1 in U-2 OS cells
contributes to attenuated activation of the p53 pathway, at
least in part by reducing (directly or indirectly) the phos-
phorylation of p53 molecules on Ser37. To the best of our
knowledge, this is the first study showing that WIP1 con-
tributes to decreased phosphorylation of this residue.
Unexpectedly, we detected a mutant version of PPM1D
gene in U-2 OS cells. To the best of our knowledge, this is
the first reported point mutation of this gene. In vitro
mutagenesis experiments performed by others showed that
the WIP1 protein truncated at the C-terminus (composed of
amino acids 1–375) is still able to inhibit phosphorylation
of Thr68 of CHK2 protein [43]. Humans express an alter-
natively spliced PPM1D mRNA in their lymphoid tissues
and in testes; this alternative form encodes amino acids
1–420 plus an additional 10 amino acids that are not
present in the major isoform of WIP1. The alternative
WIP1 also has enzymatic activity [44]. These results sug-
gest that if a C-terminally truncated mutant protein is
expressed, it can still carry out some of the wild-type
functions. However, we do not have evidence that the
protein truncated by the mutation we found is present in
cells at a detectable level; indeed, we have some reason to
believe that it is not. Because the mutation shortens the
reading frame by 25 %, the expected molecular weight of
the mutant protein is 50 kDa. However, using the anti-
WIP1 antibody, we have not detected any protein of
molecular weight lower than wild-type WIP1 (66.7 kDa) or
higher than 43 kDa that was present specifically in U-2 OS
cells (Fig. 4). The immunogen for this antibody was
derived from within residues 200–300 of human WIP1, so
it should be able to detect the truncated version of the
protein. Hence, we speculate that the mutant gene encodes
an unstable protein, whereas for reasons yet to be deter-
mined, the wild-type allele of the gene in U-2 OS cells
produces an amount of WIP1 that is larger than that in
A549 cells.
It is surprising to find a mutation that generates a stop
codon in an overexpressed oncogene. Is it a coincidence
that U-2 OS cells harbor a nonsense mutation in PPM1D
and also apparently overexpress the encoded protein from
the wild-type allele, or are these two phenomena somehow
related? Are PPM1D point mutations common in human
cancers? Further research is warranted to answer these
important questions.
In conclusion, we report that resveratrol at 50 lM
concentration activates DNA-damage signaling and the
p53 pathway, as well as reduces the replicative potential of
cancer cell lines. The upregulation of p53 by the nutlin-3a
in resveratrol-exposed cells reduces the activation of DNA-
damage signaling, increases the frequency of cells in the
G1 phase of the cell cycle, and prevents the loss of repli-
cative potential. These findings indicate that the genotoxic
and cytostatic activities of resveratrol depend on cell-cycle
progression. The activation of the p53 pathway in resve-
ratrol-exposed U-2 OS cells is attenuated relative to that
observed in A549 cells. U-2 OS cells exhibit increased
expression of the p53 antagonist PPM1D, but shRNA-
mediated knockdown of this protein only slightly increases
the activation of p53. Unexpectedly, in U-2 OS cells, one
allele of PPM1D gene contains a nonsense mutation. The
molecular consequences of this mutation will be a subject
of future investigations.
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